Altered topographic expression of p21(WAF1/CIP1/SDI1), bcl2 and p53 during gastric carcinogenesis

Pathology Research and Practice

Volumn 194, Issue 5, 1998, Pages 309-317

  Cho, Jeong Hee ^a   Kim, Woo Ho ^b  

^a Dankook University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

bcl2 and p53; Direct DNA sequencing; Gastric carcinogenesis; Immunohistochemistry; p21(WAF1 CIP1 SDI1); PCR SSCP

Indexed keywords

PROTEIN BCL 2; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE; CELLULAR DISTRIBUTION; DNA SEQUENCE; EPITHELIUM CELL; EPITHELIUM DYSPLASIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; STOMACH CARCINOGENESIS; STOMACH MUCOSA; STOMACH POLYP;

EID: 0031841364     PISSN: 03440338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0344-0338(98)80054-X     Document Type: Article

References (27)

1. Bronner MP, Culin C, Reed JC, Furth Emma E (1995) The bcl-2 protooncogene and the gastrointestinal epithelial tumor progression mode. Am J Pathol 146: 20-26
2. Cho JH, Noguchi M, Ochiai A, Uchino S, Hirohashi S (1994) Analysis of regional difference of p53 mutation in advanced gastric carcinoma: Relation to heterogeneous differentiation and invasiveness. Mod Pathol 7: 205-211
3. Cho JH, Noguchi M, Ochiai A, Hirohashi S (1996) Loss of heterozygosity of multiple tumor suppressor genes in human gastric cancers by polymerase chain reaction. Lab Invest 74: 835-841
4. El-Diery WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Linzer KW, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825
5. WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 55: 2910-2929
6. Harper JW, Adami GR, Wei N, Keyonmarsi K, Elledge SJ (1993) The p21 cell-interacting protein Cip1 is a potent inhibitor of Cl cyclin-dependent kinases. Cell 75: 805-816
7. Hockenbery DM, Zutter M, Hickey W, Nahm M, Kosmeyer SJ (1991) Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88: 6961-6965
8. Kastan MB, Zhan Q, El-diery WS, Carrier F, Jack T, Walsh WV, Plunkett BS (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is effective in ataxia-telangiectasia. Cell 71, 587-598
9. Kim JP, Yang HK, Oh ST (1991) Comparison of survival curves of gastric cancer patients according to old, new and modified UICC classification. In: Proceedings of the Tenth Asia Pacific cancer Conference, p 443. International Acadenomc Publisher, Beijing
10. Kolodziejczyk P, Yao T, Oya M, Nakamura S, Utsunomiya T, Ishikawa T, Tsuneyoshi M (1994) Long term follow-up study of patients with gastric adenomas with malignant transformation. Cancer 74: 2896-2907
11. Lauren P (1965) The two histological main types of gastric carcinoma; diffuse and so-called intestinal-type carcinoma. An attempt at histochemical classification. Acta Pathol Microbiol Scand 64: 31-49
12. Levine AJ (1993) The tumor suppressor genes. Annu Rev. Biochem 62: 623-651
13. Lebrun DP, Warnke RA, Cleary ML (1993) Expression of bcl-2 in fetal tissue suggests a role in morphogenesis. Am J Pathol 142: 742-753
14. McDonnell TJ, Korsmeyer SJ (1991) Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14:18). Nature 393: 254-256
15. Merritt AJ, Potten CS, Kemp CJ, Hickman JA, Balmain A, Lane DP, Hall PA (1994) The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 54: 614-617
16. WAF1/CIP1 gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction. Human Pathol 27: 1211-1220
17. Pennie JS, Jackqueline ML, Maria JB, Filip MI (1994) p53 expression in Barret's esophagus, dysplasia and adenocarcinoma using antibody DO-7. J Pathol 73: 221-226
18. Silvestrini R, Veneroni S, Daidone MG, Bowini E, Boracchi P, Mezzetti M, Fronzo GD, Rilke F, Veronesi U (1994) Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lympho node-negative breast cancer patients. J Natl Cancer Inst 86: 499-504
19. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee J, Levin B (1995) bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 55: 237-241
20. Tahara E (1993) Molecular mechanism of stomach carcinogenesis. J Cancer Res Clin Oncol 199: 1-8
21. Tsujimoto Y, Croce CM (1986) Analysis of the structure, transcripts and protein product of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83: 5214-5218
22. Upadhyay S, Li G, Liu H, Chwn YQ, Sarkar FH, Kim HRC (1995) bcl2 suppressed expression of p21/WAF1/Cip1 in breast epithelial cells. Cancer Res 55: 4520-4524
23. Waga S, Hannon GJ, Beach D, Stillman B (19949) The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature (Lond) 369: 574-578
24. Wang Y, Szekely L, Okan I, Klein G, Wiman RG (1993) Wild-type p53-triggered apoptosis is inhibited by bcl2 in a v-myc induced T-cell lymphoma cell line. Oncogene 8: 3427-3431
25. Wynford-Thomas D (1992) p53 in tumor pathology: can we trust immunocytochemistry? J of Pathol 766: 329-330
26. Wu X, Bayle JH, Olson D, Levine AJ (1993) The p53-mdm2 autoregulatory feedback loop. Genes Dev 7: 1126-1132
27. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D (1993) p21 is a universed inhibitor of cyclin kinases. Nature (Lond) 366: 701-704